Once again, this year has seen the rise of both our 2-year and 5-year impact factor. However, a more relevant and exciting impact has been our widening reach, strong contributions, and diversity of authorship. We have had multidisciplinary studies and reports from every continent and many international collaborative works. In addition to Spanish and Portuguese translations of abstracts (courtesy of the Academia Latinoamericana de Desarrollo Infantil y Discapacidades), we published invited editorials in those languages as well as in Chinese, Japanese, and Korean. Several commentaries offered perspectives from lived experience (e.g. parents, the dancer Jerron Herman), or policymaking/shaping institutions (e.g. European Parliament and the United Nations High Commissioner for Refugees) as well as from expert clinicians and researchers. Among hot topics in the 2019 volume, mental health in cerebral palsy (CP) was addressed by several studies, highlighting bullying and the emerging influence of social media, and emphasizing the need to identify protective factors for individuals with CP and their families. A clearer picture of cardiovascular risk, disease, and mortality in adults with CP is also emerging thanks to a handful of papers whose conclusions invite readers to apply and evaluate proactive and preventive measures to optimize nutrition, sleep, and physical activity in these individuals. Assessment of visual functioning in disabled children remains a challenging issue but several important papers published in 2019 presented promising tools. The Visual Function Classification System for children with CP is likely to become an indispensable companion to the other classification systems that are being used universally. Classifications and scales were presented or further evaluated for a number of other symptoms and functions, including pain, fatigue, hand function, communication, and to predict eating and drinking difficulties. In the context of the public debate (often ill-informed) about cannabis-derived therapies, one paper clarified the efficacy, safety, and tolerability of cannabidiol in paediatric epilepsy and the clinical challenges associated with its use. Another paper synthesized available studies on the effect of tetrahydrocannabinol on spasticity (mostly in adults with multiple sclerosis) and concluded that there is currently insufficient evidence to support the use of cannabinoids in the treatment of spasticity in children. A review of nusine rsen treatment of spinal muscular atrophy identified gaps in the knowledge of its effectiveness, including in patient groups in which proof of efficacy has been documented. To approach these issues in a systematic, rigorous, and transparent way, we now welcome scoping reviews. The goal is to ‘scope out’ available evidence in emerging clinical areas in order to provide an overview of the current state of research as well as to identify gaps in the evidence to guide future studies. One example was a scoping review of CP research in India. It found a focus on interventions to reduce impairment, while activities, participation, and environmental factors are addressed only minimally. This review also documented that many of the studies are published in journals that are not indexed in worldwide databases of scholarly journals. In the course of this year, we also continued to refine the editorial process for systematic reviews. One major collaborative work followed a systematic review methodology that resulted in clinical practice recommendations on developmental coordination disorder that we anticipate will reshape practice, research, and the evolution of the concept of the condition itself. Finally, I was particularly glad this year to receive the 50-year update on a cohort of individuals with surgically treated spina bifida. The study provided a very long-term perspective through marked evolution in treatment, service, and attitudes towards disability, emphasizing the need for a proactive, lifelong outlook in developmental disability. We look forward to publishing and learning from new studies in Volume 62.

中文翻译：

---

DMCN 2019 亮点：医用大麻、发育性协调障碍指南、脑瘫心血管疾病等

今年再次见证了我们的 2 年和 5 年影响因子的上升。然而，更相关和令人兴奋的影响是我们不断扩大的影响范围、强大的贡献和作者的多样性。我们有来自各大洲的多学科研究和报告以及许多国际合作作品。除了摘要的西班牙语和葡萄牙语翻译（由 Academia Latinoamericana de Desarrollo Infantil y Discapacidades 提供），我们还发表了这些语言以及中文、日语和韩语的特邀社论。一些评论提供了来自生活经验（例如父母、舞者 Jerron Herman）或政策制定/塑造机构（例如欧洲议会和联合国难民事务高级专员）以及专家临床医生和研究人员的观点。在 2019 年的热门话题中，脑瘫 (CP) 的心理健康通过多项研究得到解决，强调了欺凌和社交媒体的新兴影响，并强调需要确定脑瘫患者及其家人的保护因素。由于少数论文的结论邀请读者应用和评估主动和预防措施以优化这些人的营养、睡眠和身体活动，因此对患有 CP 的成年人的心血管风险、疾病和死亡率的更清晰的描述也正在出现。残疾儿童视觉功能的评估仍然是一个具有挑战性的问题，但 2019 年发表的几篇重要论文提出了有希望的工具。CP 儿童的视觉功能分类系统很可能成为其他普遍使用的分类系统不可或缺的伴侣。针对许多其他症状和功能，包括疼痛、疲劳、手部功能、交流以及预测饮食困难，提出或进一步评估了分类和量表。在关于大麻衍生疗法的公开辩论（通常消息不灵通）的背景下，一篇论文阐明了大麻二酚在小儿癫痫中的疗效、安全性和耐受性以及与其使用相关的临床挑战。另一篇论文综合了关于四氢大麻酚对痉挛（主要是患有多发性硬化症的成年人）影响的现有研究，并得出结论认为，目前没有足够的证据支持使用大麻素治疗儿童痉挛。对 nusine rsen 治疗脊髓性肌萎缩症的回顾发现了对其有效性知识的认识上的差距，包括在已记录有效性证明的患者组中。为了以系统、严谨和透明的方式处理这些问题，我们现在欢迎范围界定审查。目标是“确定”新兴临床领域的可用证据，以提供对当前研究状态的概述，并确定证据中的差距以指导未来的研究。一个例子是对印度 CP 研究的范围审查。它发现重点放在减少损害的干预措施上，而活动、参与和环境因素只得到最低限度的解决。该评论还记录了许多研究发表在未在全球学术期刊数据库中编入索引的期刊上。在这一年中，我们还继续完善系统评价的编辑流程。一项主要的合作工作遵循系统评价方法，产生了关于发育性协调障碍的临床实践建议，我们预计这将重塑实践、研究和疾病本身概念的演变。最后，今年我特别高兴地收到了一组接受手术治疗的脊柱裂患者的 50 年更新。该研究通过治疗、服务和对残疾的态度的显着演变提供了一个非常长远的观点，强调需要对发展性残疾采取积极主动的终身展望。我们期待在第 62 卷中发表新研究并从中学习。